Cargando…
An Expert, Multidisciplinary Perspective on Best Practices in Biomarker Testing in Intrahepatic Cholangiocarcinoma
Intrahepatic cholangiocarcinoma (iCCA) is a rare and aggressive malignancy that arises from the intrahepatic biliary tree and is associated with a poor prognosis. Until recently, the treatment landscape of advanced/metastatic iCCA has been limited primarily to chemotherapy. In recent years, the adve...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9526481/ https://www.ncbi.nlm.nih.gov/pubmed/35925597 http://dx.doi.org/10.1093/oncolo/oyac139 |
_version_ | 1784800884606107648 |
---|---|
author | Madoff, David C Abi-Jaoudeh, Nadine Braxton, David Goyal, Lipika Jain, Dhanpat Odisio, Bruno C Salem, Riad Schattner, Mark Sheth, Rahul Li, Daneng |
author_facet | Madoff, David C Abi-Jaoudeh, Nadine Braxton, David Goyal, Lipika Jain, Dhanpat Odisio, Bruno C Salem, Riad Schattner, Mark Sheth, Rahul Li, Daneng |
author_sort | Madoff, David C |
collection | PubMed |
description | Intrahepatic cholangiocarcinoma (iCCA) is a rare and aggressive malignancy that arises from the intrahepatic biliary tree and is associated with a poor prognosis. Until recently, the treatment landscape of advanced/metastatic iCCA has been limited primarily to chemotherapy. In recent years, the advent of biomarker testing has identified actionable genetic alterations in 40%-50% of patients with iCCA, heralding an era of precision medicine for these patients. Biomarker testing using next-generation sequencing (NGS) has since become increasingly relevant in iCCA; however, several challenges and gaps in standard image-guided liver biopsy and processing have been identified. These include variability in tissue acquisition relating to the imaging modality used for biopsy guidance, the biopsy method used, number of passes, needle choice, specimen preparation methods, the desmoplastic nature of the tumor, as well as the lack of communication among the multidisciplinary team. Recognizing these challenges and the lack of evidence-based guidelines for biomarker testing in iCCA, a multidisciplinary team of experts including interventional oncologists, a gastroenterologist, medical oncologists, and pathologists suggest best practices for optimizing tissue collection and biomarker testing in iCCA. |
format | Online Article Text |
id | pubmed-9526481 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-95264812022-10-03 An Expert, Multidisciplinary Perspective on Best Practices in Biomarker Testing in Intrahepatic Cholangiocarcinoma Madoff, David C Abi-Jaoudeh, Nadine Braxton, David Goyal, Lipika Jain, Dhanpat Odisio, Bruno C Salem, Riad Schattner, Mark Sheth, Rahul Li, Daneng Oncologist Hepatobiliary Intrahepatic cholangiocarcinoma (iCCA) is a rare and aggressive malignancy that arises from the intrahepatic biliary tree and is associated with a poor prognosis. Until recently, the treatment landscape of advanced/metastatic iCCA has been limited primarily to chemotherapy. In recent years, the advent of biomarker testing has identified actionable genetic alterations in 40%-50% of patients with iCCA, heralding an era of precision medicine for these patients. Biomarker testing using next-generation sequencing (NGS) has since become increasingly relevant in iCCA; however, several challenges and gaps in standard image-guided liver biopsy and processing have been identified. These include variability in tissue acquisition relating to the imaging modality used for biopsy guidance, the biopsy method used, number of passes, needle choice, specimen preparation methods, the desmoplastic nature of the tumor, as well as the lack of communication among the multidisciplinary team. Recognizing these challenges and the lack of evidence-based guidelines for biomarker testing in iCCA, a multidisciplinary team of experts including interventional oncologists, a gastroenterologist, medical oncologists, and pathologists suggest best practices for optimizing tissue collection and biomarker testing in iCCA. Oxford University Press 2022-08-04 /pmc/articles/PMC9526481/ /pubmed/35925597 http://dx.doi.org/10.1093/oncolo/oyac139 Text en © The Author(s) 2022. Published by Oxford University Press. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Hepatobiliary Madoff, David C Abi-Jaoudeh, Nadine Braxton, David Goyal, Lipika Jain, Dhanpat Odisio, Bruno C Salem, Riad Schattner, Mark Sheth, Rahul Li, Daneng An Expert, Multidisciplinary Perspective on Best Practices in Biomarker Testing in Intrahepatic Cholangiocarcinoma |
title | An Expert, Multidisciplinary Perspective on Best Practices in Biomarker Testing in Intrahepatic Cholangiocarcinoma |
title_full | An Expert, Multidisciplinary Perspective on Best Practices in Biomarker Testing in Intrahepatic Cholangiocarcinoma |
title_fullStr | An Expert, Multidisciplinary Perspective on Best Practices in Biomarker Testing in Intrahepatic Cholangiocarcinoma |
title_full_unstemmed | An Expert, Multidisciplinary Perspective on Best Practices in Biomarker Testing in Intrahepatic Cholangiocarcinoma |
title_short | An Expert, Multidisciplinary Perspective on Best Practices in Biomarker Testing in Intrahepatic Cholangiocarcinoma |
title_sort | expert, multidisciplinary perspective on best practices in biomarker testing in intrahepatic cholangiocarcinoma |
topic | Hepatobiliary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9526481/ https://www.ncbi.nlm.nih.gov/pubmed/35925597 http://dx.doi.org/10.1093/oncolo/oyac139 |
work_keys_str_mv | AT madoffdavidc anexpertmultidisciplinaryperspectiveonbestpracticesinbiomarkertestinginintrahepaticcholangiocarcinoma AT abijaoudehnadine anexpertmultidisciplinaryperspectiveonbestpracticesinbiomarkertestinginintrahepaticcholangiocarcinoma AT braxtondavid anexpertmultidisciplinaryperspectiveonbestpracticesinbiomarkertestinginintrahepaticcholangiocarcinoma AT goyallipika anexpertmultidisciplinaryperspectiveonbestpracticesinbiomarkertestinginintrahepaticcholangiocarcinoma AT jaindhanpat anexpertmultidisciplinaryperspectiveonbestpracticesinbiomarkertestinginintrahepaticcholangiocarcinoma AT odisiobrunoc anexpertmultidisciplinaryperspectiveonbestpracticesinbiomarkertestinginintrahepaticcholangiocarcinoma AT salemriad anexpertmultidisciplinaryperspectiveonbestpracticesinbiomarkertestinginintrahepaticcholangiocarcinoma AT schattnermark anexpertmultidisciplinaryperspectiveonbestpracticesinbiomarkertestinginintrahepaticcholangiocarcinoma AT shethrahul anexpertmultidisciplinaryperspectiveonbestpracticesinbiomarkertestinginintrahepaticcholangiocarcinoma AT lidaneng anexpertmultidisciplinaryperspectiveonbestpracticesinbiomarkertestinginintrahepaticcholangiocarcinoma AT madoffdavidc expertmultidisciplinaryperspectiveonbestpracticesinbiomarkertestinginintrahepaticcholangiocarcinoma AT abijaoudehnadine expertmultidisciplinaryperspectiveonbestpracticesinbiomarkertestinginintrahepaticcholangiocarcinoma AT braxtondavid expertmultidisciplinaryperspectiveonbestpracticesinbiomarkertestinginintrahepaticcholangiocarcinoma AT goyallipika expertmultidisciplinaryperspectiveonbestpracticesinbiomarkertestinginintrahepaticcholangiocarcinoma AT jaindhanpat expertmultidisciplinaryperspectiveonbestpracticesinbiomarkertestinginintrahepaticcholangiocarcinoma AT odisiobrunoc expertmultidisciplinaryperspectiveonbestpracticesinbiomarkertestinginintrahepaticcholangiocarcinoma AT salemriad expertmultidisciplinaryperspectiveonbestpracticesinbiomarkertestinginintrahepaticcholangiocarcinoma AT schattnermark expertmultidisciplinaryperspectiveonbestpracticesinbiomarkertestinginintrahepaticcholangiocarcinoma AT shethrahul expertmultidisciplinaryperspectiveonbestpracticesinbiomarkertestinginintrahepaticcholangiocarcinoma AT lidaneng expertmultidisciplinaryperspectiveonbestpracticesinbiomarkertestinginintrahepaticcholangiocarcinoma |